Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPDC-FuHu
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
TPDC-FuHu is a six-drug chemotherapy regimen designed to improve the efficacy of lomustine (CCNU) in treating recurrent metastatic brain tumors. The regimen consists of thioguanine (T), procarbazine (P), dibromodulcitol (D), lomustine/CCNU (C), fluorouracil (Fu), and hydroxyurea (Hu). The first four drugs are administered first to enhance CCNU-induced tumor-cell kill and reduce alkyltransferase repair of ethylated DNA. Two weeks later, the fluorouracil-hydroxyurea combination is given to kill cells that began to cycle after the challenge of the first four drugs.
- Other names
- thioguanine + procarbazine + dibromodulcitol + lomustine + fluorouracil + hydroxyurea
Beyond the preview
Go deeper on TPDC-FuHu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPDC-FuHu.